Subject: NIH GUIDE - V20(45) 11/29/91
From: Dot Baker <[email-masked]>
To: [email-masked]
Cc: [email-masked], [email-masked], [email-masked]
Date: Mon, 02 Dec 91 13:21 EST

Hi Paul,
    The ll/29/9l NIH Guide has arrived.  Please post to the NIH
Listserver as:   NIHGUIDE.911129
                          Thanks.   Dottie
Note for Paul and others.   This is the only transmission for this
NIH Guide.  There are no separate RFAs.
    Have a nice day.
                    Dottie
$$XID NIHGUIDE 19911129 V20N45 P1O1 ************************************
No RFAs present
 
NIH GUIDE - Vol. 20, No. 45 - November 29, 1991
 
$$INDEX BEGIN *******************************************************
 
                               NOTICES
 
$$INDEX N1 **********************************************************
 
NOTICE OF SKIPPED GUIDE PUBLICATION
 
$$INDEX N2 **********************************************************
 
NOTICE OF REGIONAL MEETINGS
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH
 
$$INDEX N3 **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
National Institutes of Health
Food and Drug Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; FOOD AND DRUG ADMINISTRATION
 
                             NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 **********************************************************
 
UNITED STATES RENAL DATA SYSTEM (RFP NIH-NIDDK-92-2)
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX:  DIABETES, DIGESTIVE, KIDNEY DISEASES
 
$$INDEX R2 03/03/92 *************************************************
 
RESEARCH ON PHARMACOLOGIC TREATMENTS FOR ALCOHOLISM (RFA AA-92-01)
National Institute on Alcohol Abuse and Alcoholism
INDEX:  ALCOHOL ABUSE, ALCOHOLISM
 
                                  ONGOING PROGRAM ANNOUNCEMENTS
 
$$INDEX P1 **********************************************************
 
RESEARCH ON HAIR TESTING FOR DRUGS OF ABUSE (PA-92-18)
National Institute on Drug Abuse
INDEX:  DRUG ABUSE
 
$$INDEX P2 **********************************************************
 
SMALL INSTRUMENTATION GRANTS PROGRAM (PA-92-19)
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH
 
$$INDEX P3 **********************************************************
 
CENTERS FOR RESEARCH ON MENTAL HEALTH SERVICES FOR CHILDREN AND
ADOLESCENTS (PA-92-20)
National Institute of Mental Health
INDEX:  MENTAL HEALTH
 
                                ERRATUM
 
$$INDEX E1 **********************************************************
 
NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS INFECTION (AI-91-13)
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES
 
$$INDEX E2 **********************************************************
 
ORPHAN RECEPTORS IN ENDOCRINOLOGY (DK-92-03)
National Institutes of Diabetes and Digestive and Kidney Disease
INDEX:  DIABETES, DIGESTIVE, KIDNEY DISEASES
 
$$INDEX END *********************************************************
 
                                           NOTICES
 
$$N1 BEGIN **********************************************************
 
NOTE:  The NIH Guide for Grants and Contracts will not be published on
December 6.  The next issue will be December 13.
 
$$N1 END ************************************************************
 
$$N2 BEGIN **********************************************************
 
NOTICE OF REGIONAL MEETINGS
 
P.T. 42; K.W. 1014006, 1014002
 
National Institutes of Health
 
The National Institutes of Health (NIH) has been engaged in a strategic
planning process aimed at developing the Agency's first corporate long-
range Strategic Plan.  The purpose of the NIH Strategic Plan is to:
(1) identify areas of research that promise extraordinary dividends for
the Nation's future health, (2) nurture the intellectual base of
biomedical research and the conditions that lead to breakthroughs on
the cutting edge of science, and (3) provide approaches for addressing
broad administrative and science policy issues that affect the ability
of the NIH to carry out its mandate.  The Strategic Plan incorporates
the ideas of all the organizational components of the NIH as well as
the research components of the Alcohol, Drug Abuse, and Mental Health
Administration (ADAMHA).
 
The NIH will convene two regional meetings to provide a forum for the
extramural community to comment on the draft Strategic Plan before it
is finalized.  The first meeting will take place on February 12, 1992,
at Occidental College, Los Angeles, California, and will be co-hosted
by Occidental College and the Charles R. Drew University of Medicine
and Science.  The second meeting will be held on February 25, at the
University of Connecticut Health Center, Farmington, Connecticut.
 
Each of the regional meetings will be of one day duration, beginning at
9 a.m. and ending at 3 p.m.  The meetings will begin with the NIH
Director presenting an overview of the NIH Strategic Plan.  Immediately
afterwards, representatives of concerned organizations and institutions
will be invited to present testimony before a panel of senior NIH
officials, to be chaired by the Director, NIH.  Due to time
constraints, it would be appreciated if only one representative from
each organization would present testimony; oral presentations will be
limited to five minutes.  Written testimony may be any length and
should include a brief description of the organization presenting.
Testimony will be scheduled based upon when notification of intent to
present testimony is received.  If the number of organizations that
want to present oral testimony exceeds the time available on the
agenda, the individual written statements will serve as testimony
presented.  All testimony, whether oral or written, will form a part of
the official record of the NIH Strategic Plan.
 
If you or others from your organization who plan to attend one of these
regional meetings have any special needs that require assistance,
please inform the office listed below.  If you have questions
concerning either of the two regional meetings, please contact Ms. Mary
Demory (301) 496-1454.
 
If you will be attending one of the regional meetings or if your
organization would like to testify before the NIH panel, please provide
the name, title, institution, telephone number, and mailing address of
the individual attending.  Indicate which regional meeting and whether
or not testimony will be presented.  The requested information is to be
sent by mail or facsimile no later than December 16, 1991 to:
 
NIH Strategic Plan Regional Meetings
c/o Dr. Jay Moskowitz
NIH, Building 1, Room 103
9000 Rockville Pike
Bethesda, MD  20892
FAX:  (301) 402-1759
 
A copy of the Draft NIH Strategic Plan and additional information will
be sent prior to the regional meetings to participants attending and/or
testifying.
 
$$N2 END ************************************************************
 
$$N3 BEGIN **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
 
P.T. 42; K.W. 0783005
 
National Institutes of Health
Food and Drug Administration
 
The National Institutes of Health (NIH) and the Food and Drug
Administration (FDA) are sponsoring a series of workshops on the
responsibilities of researchers, Institutional Review Boards (IRBs),
and institutional officials for the protection of human subjects in
research.  The workshops are open to everyone with an interest in
research involving human subjects.  The meetings should be of special
interest to those persons currently serving or about to begin serving
as a member of an IRB.  Issues discussed at these workshops are
relevant to all other Public Health Service agencies.  The current
schedule includes the following:
 
WEST COAST WORKSHOP
 
DATES:  January 23 and 24, 1992 (REVISED DATES)
 
WORKSHOP SITE:  Los Angeles, CA
 
SPONSORS:
University of Southern California
Los Angeles, CA  90089-4014
 
California State University - Los Angeles
5151 State University Drive
Los Angeles, CA  90032-8202
 
REGISTRATION CONTACT:
Ms. Lily Patterson
Assistant to the Director
Research and Sponsored Programs
California State University - Los Angeles
5151 State University Drive
Los Angeles, CA  90032-8202
Telephone:  (213) 343-3820
 
TOPIC:  Whose Research is it Anyway?  A Workshop on the Protection of
Human Subjects in Research
 
SOUTH MIDWESTERN WORKSHOP
 
DATES:  February 20 and 21, 1992
 
WORKSHOP SITE:  San Antonio, TX
 
SPONSORS:
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX  78284-7972
 
St. Mary's University
One Camino Santa Maria
San Antonio, TX  78228-8572
 
REGISTRATION CONTACT:
Ms. Angie Khan
Institutional Coordinator of Research Review
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive (Room 402L)
San Antonio, TX  78284-7972
Telephone:  (512) 567-2351
 
TOPIC:  Identifying and Assessing Risks in Human Subject Research
 
For further information regarding these workshops and future NIH/FDA
National Protection of Human Subjects Workshops, please contact:
 
Ms. Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101
 
$$N3 END ************************************************************
 
                           NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN NIH-NIDDK-92-2 *******************************************
 
UNITED STATES RENAL DATA SYSTEM
 
RFP AVAILABLE:  NIH-NIDDK-92-2
 
P.T. 34; K.W. 0755018, 0780030, 1010013, 0785055
 
National Institute of Diabetes and Digestive and Kidney Diseases
 
The National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), Division of Kidney, Hematology and Urology (DKUH) has a
requirement to continue the Coordinating Center (CC) for the United
States Renal Data System (USRDS).  The CC, in coordination with the
NIDDK and the Health Care Financing Administration (HCFA), shall
provide the medical, biostatistical, epidemiological, data management,
and analytical expertise to maintain and update the database.  Equally
important functions of the CC will be the coordination, scientific
management, development, and expansion of the database, data analysis,
preparation, and release of subset(s) of the database to support
investigator-initiated research, and publications of papers and reports
of scientific findings based on USRDS data.  This program will be
undertaken through the joint efforts of the NIDDK/DKUH and the HCFA
Bureau of Data Management and Strategy, Health Standards and Quality
Bureau, and the ESRD Networks or equivalent system in close
collaboration with the United States nephrology and renal transplant
communities and the major specialty organizations.
 
The Request for Proposals (RFP) NIH-NIDDK-92-2 will be released on or
about November 29, 1991, with a closing date on or about March 31,
1992.  To receive a copy of this RFP, supply this office with two self
addressed mailing labels and cite the RFP number referenced above.
Requests must be in writing and addressed to:
 
Patrick M. Sullivan
Contracting Officer, Contracts Management Branch
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 602
Bethesda, MD  20892
 
This advertisement does not commit the Government to make an award.
 
$$R1 END ************************************************************
 
$$R2 BEGIN AA-92-01 *************************************************
 
RESEARCH ON PHARMACOLOGIC TREATMENTS FOR ALCOHOLISM
 
RFA AVAILABLE:  AA-92-01
 
P.T. 34; K.W. 0404003, 0710100, 0740020
 
National Institute on Alcohol Abuse and Alcoholism
 
Application Receipt Date:  April 3, 1992
 
PURPOSE
 
Development of new medications for the treatment of brain and behavior
disorders is a priority of the Alcohol, Drug Abuse,and Mental Health
Administration (ADAMHA).  As part of this initiative, the National
Institute on Alcohol Abuse and Alcoholism (NIAAA) is seeking
applications for grants in the area of clinical pharmacological
treatments for alcoholism.  The Request for Applications (RFA),
available from the program administrators listed below, briefly
discusses current knowledge on pharmacologic therapies, some specific
research questions under each topic, broader issues that "cut across"
pharmacotherapy in the treatment of alcoholism, key study design
considerations, procedures for submission and review of grant
applications, and terms and conditions for grant support.  The RFA
deals with a range of pharmacological agents at various stages of
research development, ranging from preclinical research and development
to Food and Drug Administration (FDA) approval.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Research on Pharmacologic Treatments for Alcoholism, is related to the
priority area of alcohol abuse reduction.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0, or Summary Report:  Stock No. 017-001-00473-1) through
the Superintendent of Documents, Government Printing Office,
Washington, DC  20402-9325 (telephone 202-783-3238).
 
ELIGIBILITY
 
Applications may be submitted by domestic and foreign, nonprofit and
for-profit public and private organizations such as universities,
colleges, hospitals, laboratories, units of State or local governments,
and eligible agencies of the Federal Government.  Women and minority
investigators are encouraged to apply.
 
MECHANISMS OF SUPPORT
 
Research support may be requested through applications for an
individual research grant (R01), small grant (R03), First Independent
Research Support and Transition (FIRST) Award (R29), and
exploratory/developmental grants (R21).  Applicants who are interested
in applying for a FIRST Award (R29), Exploratory/Developmental Grant
(R21), or Small Grant (R03) may request additional information about
these funding mechanisms from the National Clearinghouse for Alcohol
and Drug Information, P.O. Box 2345, Rockville, MD  20852, telephone
(301) 468-2600.
 
AVAILABILITY OF FUNDS
 
In FY 1992, it is anticipated that approximately $2,300,000 will be
available to support approximately 10 to 20 new grants, depending on
the mechanism of support, under this RFA.  This level of support is
dependent on the receipt of a sufficient number of applications of high
scientific merit. Although this program is provided for in the
financial plans of the NIAAA, the award of grants pursuant to this RFA
is also contingent upon the availability of funds for this purpose.
 
BACKGROUND AND AREAS OF RESEARCH
 
Over the past decade, research activity on the pharmacological
treatment of alcohol dependency has burgeoned (Litten and Allen, 1991).
As a result, many types of pharmacological agents have been employed in
the various situations encountered in clinical practice.  The
pharmacological agents for managing the clinical events can be divided
into the following categories (Liskow and Goodwin, 1987):
 
Anticraving agents
Aversive agents
Agents to treat acute alcohol withdrawal
Agents to treat the protracted withdrawal syndrome
Agents to diminish drinking by treating associated psychiatric
pathology
Agents to decrease drinking by treating associated drug abuse
Agents to induce sobriety in intoxicated individuals (amethystic
agents)
 
Research is needed to resolve questions within each of these classes of
pharmacological agents.  Research is also needed to address general
questions that transcend specific pharmacological classes.  The
following provides a background on each of the classes of
pharmacological agents listed, describes general, cross-cutting
research issues in the area of pharmacotherapy, and identifies some
specific research questions.  The discussion of any agent within this
announcement is not to be considered a comprehensive appraisal of its
effectiveness nor an endorsement of its suitability for clinical trial.
 
GENERAL RESEARCH QUESTIONS IN PHARMACOTHERAPY
 
Even though research efforts on alcoholism treatment have expanded over
the past decade, a wide range of general research questions remain in
developing effective alcoholism treatments that employ
pharmacotherapeutic agents.  These include:
 
o  What are the precise conditions that are amenable to pharmacological
interventions?  How can psychosocial and behavioral interventions be
integrated with pharmacotherapy to enhance treatment outcome?  What
should be the short-and long-term goals of these interventions?
 
o  What psychological and biomedical variables are associated with
responsiveness to alcoholism medications in general and specific agents
or classes of agents?
 
o  Is the concept of matching specific treatments to different aspects
of alcoholism (e.g., alcohol subtypes, comorbid psychopathology, and
primary versus secondary alcoholism) more efficacious than a more
generalized medicational approach to treatment?
 
o  Does collateral pharmacological treatment enhance or detract from
participation in traditional alcoholism treatment and sobriety support
groups?
 
o  What are the most effective research/statistical methodologies for
conducting pharmacologic research on alcoholism treatment?
 
o  How can alcohol abuse phenomena be quantified to assess more
precisely the impact of psychopharmacological agents?
 
o  How can treatment compliance be measured during pharmacotherapy?
 
o  What are the long-range effects of pharmacotherapy?
 
STUDY DESIGN CONSIDERATIONS
 
Well-designed studies need to be conducted to answer research questions
such as those listed above.  These studies must include the use of
appropriate control groups (i.e., double blind studies) with adequate
sample sizes and employment of proper statistical analyses.  In
addition, all treatment interventions must be specified.  Although
developmental projects may employ highly homogeneous samples in a
single setting, it is desirable in later-stage research to include
greater heterogeneity in samples and sites.  Finally, efficacy studies
need to measure compliance and adequately verify self-reports.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
For projects involving clinical research, ADAMHA requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women and minorities are not included in the
study populations, a specific and compelling justification for this
exclusion must be provided.  Applications that do not include women and
minorities and that are without such documentation will not be accepted
for review.
 
APPLICATION PROCESS
 
Applicants must use the grant application form PHS 398 (rev. 10/88).
The number and title of this RFA, "AA-92-01, Research on Pharmacologic
Treatments for Alcoholism," must be typed in item 2 on the face page of
the PHS 398 application form.
 
When using the PHS 398 application form to respond to an RFA,
applicants must staple the RFA label, printed in the application kit,
to the bottom of the face page.  Failure to use this label could result
in delayed processing of the application, such that it may not reach
the review committee in time for review.
 
The signed original and five permanent legible copies of the completed
application should be sent to:
 
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892 **
 
In addition, one copy must be sent directly to:
 
Office of Scientific Affairs
National Institute on Alcohol Abuse and Alcoholism
Parklawn Building, Room 16C-20
Rockville, MD  20857
Telephone:  (301) 443-4375
 
INQUIRIES
 
Potential applicants are encouraged to request a copy of the RFA and
may contact the individuals listed below for consultation in preparing
an application under this RFA.  Direct inquiries regarding to program
issues to:
 
Division of Clinical and Prevention Research
 
Raye Z. Litten, Ph.D.
Treatment Research Branch
Division of Clinical and Prevention Research
National Institute on Alcohol Abuse and Alcoholism
Parklawn Building, Room 14C-20
5600 Fishers Lane
Rockville, MD  20857
Telephone:  (301) 443-0796

Division of Basic Research
 
Walter Hunt, Ph.D.
Chief, Neuroscience and Behavioral Research Branch
Division of Basic Research
National Institute on Alcohol Abuse and Alcoholism
Parklawn Building, Room 16C-03
5600 Fishers Lane
Rockville, MD  20857
Telephone:  (301) 443-4223
 
Direct inquiries regarding fiscal matters to:
 
Ms. Elsie Fleming
Grants Management Branch
Office of Planning and Resource Management
National Institute on Alcohol Abuse and Alcoholism
Parklawn Building, Room 16-86
5600 Fishers Lane
Rockville, MD  20857
Telephone:  (301) 443-4703
 
REVIEW PROCESS
 
The Division of Research Grants, NIH, serves as a central point for
receipt of applications for most discretionary PHS grant programs.
Applications received under this RFA will be assigned to an Initial
Review Group (IRG) convened by the NIAAA in accordance with established
PHS Referral Guidelines.  The IRG, consisting primarily of non-Federal
scientific and technical experts, will review the applications for
scientific and technical merit.  Notification of the review
recommendations will be sent to the applicant after the initial review.
Applications will receive a second-level review by the National
Advisory Council on Alcohol Abuse and Alcoholism, whose review may be
based on policy considerations as well as scientific merit.  Only
applications recommended for consideration by the Council will be
considered for funding.
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance, No. 93.273.  Awards are made under the authority of
Sections 301 and 510 of the Public Health Service Act, as amended (42
USC 241 and 290bb).  Federal regulations at 42 CFR Part 52, "Grants for
Research Projects," and Title 45 CFR Parts 74 and 92, generic
requirements concerning the administration of grants, are applicable to
these awards.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.
 
$$R2 END ************************************************************
 
                                ONGOING PROGRAM ANNOUNCEMENTS
 
$$P1 BEGIN PA-92-18 *************************************************
 
RESEARCH ON HAIR TESTING FOR DRUGS OF ABUSE
 
PA AVAILABLE:  PA-92-18
 
P.T. 34; K.W. 1003008, 0404009, 0710100
 
National Institute on Drug Abuse
 
PURPOSE
 
The goals of this program for which a program announcement is now
available from the contact named below, are to encourage systematic
research on the use of hair testing to detect drugs of abuse in an
accurate and reliable manner and to develop the necessary procedures
and safeguards.  The purpose is to provide the scientific basis to
enable the routine use of such testing in workplace situations,
epidemiological studies, studies of the behavioral effects and medical
consequences of chronic drug use, maternal and fetal studies, and other
applications.  Specific areas of interest discussed are:
pharmacological studies, analytical studies, and cost/benefit studies.
 
RESEARCH OBJECTIVES
 
The National Institute on Drug Abuse (NIDA) is interested in exploring
the pharmacokinetics of drugs in hair and some of the factors that
would influence variability in these processes.  Studies are encouraged
that will identify the mechanisms by which drugs of abuse are
incorporated into hair; the relationship between the amount of drug
used and the concentration of the drug or its metabolites in hair; the
relationship of hair incorporation to urine elimination; the minimum
dose required to produce a positive result; the time interval between
drug use and appearance of drug in the hair shaft; the in situ
stability ,chemical and positional, of drugs; the variability of drug
incorporation and retention in hair according to race, age, sex, and
other individual differences; the extent to which externally applied
drugs (whether by sweat, glandular secretions or environmental
exposure) are retained in hair; the effect of various washing and hair
treatment procedures on the removal of externally applied drugs and
internally incorporated/bound drugs.

This program encourages research aimed at evaluating existing methods
or the development of new methodologies for the detection of drugs of
abuse in hair specimens.  Validation of these analytical techniques by
assessing their accuracy, precision, sensitivity, and specificity and
identifying ways to establish appropriate cutoffs that define
potentially false-positive or false-negative results for either
screening or confirmation procedures is strongly encouraged through
this initiative.  Research endeavors aimed at the development of
reference materials for hair testing are also of interest to NIDA.
Studies are encouraged that deal with sample preparation including
those that relate to the effectiveness of various washing procedures in
removing externally and/or internally bound drug and the effectiveness
of various sample preparation techniques.
 
The biggest costs of hair analysis are labor intensive preparation,
handling, and analysis techniques.  Instrumentation is an additional
factor.  Cost/benefit studies that compare drug testing using hair
specimens with those using body fluids, such as urine or blood, would
be extremely useful.  Benefits of hair testing, including its
non-invasiveness and the historical information it may provide, must be
weighed against potential costs.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This program
announcement, Research on Hair Testing for Drugs of Abuse, is related
to the priority area of alcohol and other drugs.  Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report:  Stock No.
017-001-00473- 1) through the Superintendent of Documents, Government
Printing Office, Washington, DC  20402-9325 (telephone:  202-783-3238).
 
MECHANISM OF SUPPORT
 
Mechanisms of support included under this announcement are limited to
Research Project Grants (R01).  Annual awards will be made subject to
continued availability of funds and progress achieved.
 
ELIGIBILITY
 
Applications may be submitted by public and private non-profit and
for-profit organizations such as universities, colleges, hospitals,
laboratories, units of State or local governments, and eligible
agencies of the Federal Government. Women and minority investigators
are encouraged to apply.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.
 
APPLICATION PROCEDURES
 
Applicants must use the research grant application form PHS 398 (rev.
10/88).  Support may be requested for a period of up to five years
(renewable for subsequent periods).  A competing supplemental
application may be submitted during an approved period of support to
expand the scope of protocol of a project during the approved period.
A competing continuation (i.e., renewal) application may be submitted
before the end of an approved period of support to continue a project.
 
RECEIPT AND REVIEW SCHEDULE
                                        Advisory
Receipt Dates       Initial             Council        Earliest
New/Renewal         Review              Review         Start Date
 
Jun 1/Jul 1*        Oct/Nov             Jan/Feb        Apr
Oct 1/Nov 1*        Feb/Mar             May/Jun        Jul
Feb 1/Mar 1*        May/Jun             Sep/Oct        Dec
 
* Competing continuation, supplemental, and revised applications are to
be submitted by these dates.
 
REVIEW PROCESS AND CRITERIA
 
Applications received under this announcement will be assigned to an
Initial Review Group (IRG) consisting primarily of non-Federal
scientific and technical experts.  Applications will receive a
second-level review by the appropriate National Advisory Council.
Criteria for scientific/technical merit review of applications will
include the following:  significance and originality from a scientific
or technical standpoint of the goals of the proposed research; adequacy
of the methodology proposed to carry out the research; feasibility of
the proposed research; qualifications and research experience of the
Principal Investigator and other key research personnel; and adequacy
of provisions for the protection of human subjects and the welfare of
animal subjects, as applicable.

 
 
AWARDS
 
Applications recommended for approval by the appropriate National
Advisory Council will be considered for funding on the basis of overall
scientific and technical merit of the research as determined by peer
review, Institute program needs and balance, and availability of funds.
 
INQUIRIES
 
Further information and consultation on this program announcement may
be obtained from:
 
Robert L. Stephenson II, M.P.H.
Division of Applied Research
National Institute on Drug Abuse
Parklawn Building, Room 9A-53
5600 Fishers Lane
Rockville, MD  20857
Telephone:  (301) 443-6780
 
A copy of the complete program announcement may be obtained from:
 
Grants Management Branch, OPRM
National Institute on Drug Abuse
5600 Fishers Lane, Room 8A-54
Rockville, MD  20857
Telephone:  (301) 443-6710
 
Questions on fiscal or grant management issues may also be directed to
this office.
 
AUTHORITY AND REGULATIONS
 
This program is described in Catalog of Federal Domestic Assistance No.
93.279.  Grants will be awarded under the authority of sections 301 and
515 of the Public Health Service Act, as amended (42 USC 241 and 290cc)
and administered in accordance with the PHS Grants Policy Statement and
Federal regulations at 42 CFR Part 52 and 45 CFR Part 74.  This program
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.
 
$$P1 END ************************************************************
 
$$P2 BEGIN PA-92-19 *************************************************
 
SMALL INSTRUMENTATION GRANTS PROGRAM
 
PA:  PA-92-19
 
P.T. 34; K.W. 0735000, 1002024, 0735015, 1014001
 
National Institutes of Health
 
Application Receipt Date:  February 12, 1992
 
BACKGROUND
 
The appropriations for the National Institutes of Health (NIH) for
Fiscal Year (FY) 1987 included, for the first time funds for grants to
purchase small instruments costing between $5,000 and $60,000.  This
action was in response to several studies of the problem of obsolete
biomedical research instrumentation that indicate that the state of
biomedical research instrumentation had seriously eroded over the
previous ten years and that this situation was retarding the progress
of biomedical research.
 
Approximately $5 million will be available from the NIH in FY 1992 for
small instrumentation grants.
 
ELIGIBILITY AND TERMS OF AWARD
 
Each institution that received $21,608 or less in support under the
Biomedical Research Support Grant (BRSG) Program in FY 1991 and
currently has active NIH research grant support is eligible to apply.
Only one application may be submitted from each eligible institution or
organizational component.  Each institution may establish its own
procedures for identifying equipment requests to be included.
 
The small instrumentation award will be restricted to the purchase of
equipment costing between $5,000 and $60,000.  Awards will be made on
or before September 30, 1992.  The amount of the award will be based
upon a percentage of the institution's research grants base for FY 1991
or $5,000, whichever is greater.
 
Specific funding decisions will depend on available funds and the
appropriateness of the request to the active projects.  Institutions
will be notified of the maximum amount for which they may apply.
 
METHOD OF APPLYING
 
Letters of instructions to eligible institutions will be mailed on or
about November 28, 1991.
 
Completed applications must be received by February 12, 1992.
 
Investigators interested in participating in their institution's
application must contact the institution's BRSG Program Director.
Institutional officials who expect to be involved in preparing an
application are requested to review the letter of instructions prior to
contacting the NIH.
 
For additional information contact:
 
Office of Research Training and Special Programs
Office of Extramural Programs
National Institutes of Health
Building 31, Room 5B44
Bethesda, MD  20892
Telephone:  (301) 496-1968
 
AUTHORITY AND REGULATIONS
 
Grants will be available under the authority of and administered in
accordance with the PHS Grants Policy Statement and Federal regulations
at 42 CFR 52 and 42 USC 241.
 
$$P2 END ************************************************************
$$P3 BEGIN PA-92-20 *************************************************
 
CENTERS FOR RESEARCH ON MENTAL HEALTH SERVICES FOR CHILDREN AND
ADOLESCENTS
 
PA AVAILABLE:  PA-92-20
 
P.T. 04, AA; K.W. 0715095, 0730050, 0403001
 
National Institute of Mental Health
 
PURPOSE
 
The National Institute of Mental Health (NIMH) announces the
availability of support for Centers on Research on Mental Health
Services for Children and Adolescents to develop multidisciplinary
research to improve the organization, financing, delivery,
effectiveness, and outcomes of mental health services for children and
adolescents.
 
This announcement addresses one of the major goals set forth in The
National Plan for Research on Child and Adolescent Mental Disorders.
It also complements the NIMH program announcement, Implementation of
the National Plan for Research on Child and Adolescent Mental
Disorders, available from NIMH, Room 9-95, 5600 Fishers Lane,
Rockville, MD 20857; telephone: (301) 443-4673.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017- 001-00473-0) or "Healthy People 2000" (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20042-9325 (telephone:
202-783-3238).  This announcement is responsive to the Healthy People
2000 Objectives in the areas of suicide attempts among adolescents
(6.2), mental disorders among children and adolescents (6.3), and
assessment by primary care providers of children's and adolescents'
cognitive, emotional, and parent-child functioning with appropriate
counseling, referral, and followup (6.4).
 
ELIGIBILITY
 
Applications may be submitted by any public and private, nonprofit and
for-profit organizations such as universities, colleges hospitals,
laboratories, units of State and local governments, and eligible
agencies of the Federal Government.  Women and minority investigators
are encouraged to apply.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
For projects involving clinical research, ADAMHA requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women and minorities are not included in the
study populations, a specific and compelling justification for this
exclusion must be provided.  Applications that do not include women and
minorities and that are without such documentation will not be accepted
for review.
 
Applicants should also be aware that the Department of Health and Human
Services has regulations for the protection of human subjects and has
developed additional regulations for the protection of children.  A
copy of these regulations, 45 CFR 46, Protection of Human Subjects, is
available from the Office for Protection from Research Risks, National
Institutes of Health, Building 31, Room 5B59, Bethesda, MD 20892.
 
METHOD OF APPLYING
 
Applications will be received under the usual PHS receipt and review
schedule.  To be considered for fiscal year 1992 funding, applications
must be complete and must be submitted by February 1, 1992.
 
All research applicants must use the grant application form PHS 398
(rev. 10/88).  Support may be requested for a period of up to five
years.  Annual awards will be made subject to continued availability of
funds and progress achieved.  A competing supplemental application may
be submitted during an approved period of support to expand the scope
or protocol of a project during the approved period.  A competing
continuation (i.e., renewal) application may be submitted before the
end of an approved period of support to continue a project.
 
Grant funds may be used for expenses clearly related and necessary to
conduct research projects, including direct costs that can be
specifically identified with the project and allowable indirect costs
of the institution. Funds may not be used to establish, add a component
to, or operate a treatment, rehabilitation, or prevention intervention
service program.  Support for research-related treatment,
rehabilitation, or prevention services and programs may be requested
only for costs required by the research.  These costs must be justified
in terms of research objectives, methods, and designs that promise to
yield generalizable knowledge and/or make significant contribution to
theoretical concepts.
 
REVIEW PROCEDURES
 
Applications will be reviewed by an initial review group (IRG)
primarily consisting of non-Federal scientific and technical experts.
Applications will receive a second-level review by the appropriate
Advisory Council based on policy considerations and scientific merit.
Only applications recommended for approval by Council may be considered
for funding.
 
Preference will be given to projects consistent with the NIMH
Public-Academic Liaison initiative (bringing together public sector
service providers and academic researchers), projects involving
high-risk populations (e.g., homeless children and adolescents, and
those with severe mental disorders), and projects that include females
and minorities in study groups.
 
INQUIRIES
 
Applicants are strongly encouraged to contact the office listed below.
Copies of the full program announcement and additional information may
be obtained by contacting:
 
Thomas L. Lalley, M.A., Chief
Kathryn M. Magruder, Ph.D., M.P.H., Assistant Chief
Kimberly Hoagwood, Ph.D.
Services Research Branch
Division of Applied and Services Research
National Institute of Mental Health
5600 Fishers Lane, Room 18-105
Rockville, MD  20857
Telephone:  (301) 443-372
 
Information on grants management issues can be obtained from:
 
Steven J. Hudak
Grants Management Section
National Institute of Mental Health
5600 Fishers Lane, Room 7C-26
Rockville, MD  20857
Telephone:  (301) 443-4596
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.242.  Under the authority of Section 301 of the Public Health
Service Act (42 U.S.C. 241), as amended, NIMH will accept applications
in response to this announcement.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
review by a Health Systems Agency.
 
$$P3 END ************************************************************
 
                                           ERRATUM
 
$$E1 BEGIN R5 19911101 APPEND RFA AI-91-13 BOTH ************************
 
NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS INFECTION
 
RFA:  AI-91-13
 
P.T. 34; K.W. 0715008, 0740020, 0755025
 
National Institute of Allergy and Infectious Diseases
 
The National Cooperative Drug Discovery Groups for the Treatment of
Human Immunodeficiency Virus Infection (NCDDG-HIV) Request for
Applications (RFA) (NIH Guide for Grants and Contracts, Vol. 20, No.
41, November 1, 1991) has been amended.  This amendment applies only to
copies of the RFA that are obtained from the Division of AIDS, National
Institute of Allergy and Infectious Diseases.  The amendment is to
clarify the purpose of the letter of intent (p.2), to state that an
NIAID peer review group will determine the competitiveness of the
application in triage (p. 22), to include acknowledgement of the recent
approval of didanosine by the Food and Drug Administration (p. 2), and
to modify the wording of the section on the Inclusion of Women and
Minorities in Basic Research Studies (pp. 21-22).

 
Copies of the modification may be obtained from:
 
Ms. Besita Wyche
Targeted Drug Discovery Section
Developmental Therapeutics Branch, Division of AIDS
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 2C11
Bethesda, MD  20892
Telephone:  (301) 496-8197
 
$$E1 END ************************************************************
 
$$E2 BEGIN R4 19911004 APPEND RFA DK-92-03 BOTH ************************
 
ORPHAN RECEPTORS IN ENDOCRINOLOGY
 
RFA:  DK-92-03
 
P.T. 34: K.W. 0785050, 0760075, 1002004, 1002008, 0710100, 1002061
 
National Institutes of Diabetes and Digestive and Kidney Disease
 
Letter of Intent Receipt Date:  December 15, 1991
Application Receipt Date:  January 24, 1992
 
This Request for Applications was published in the NIH Guide for Grants
and Contracts on October 4, 1991, Vol. 20, No. 37.  The applications
will be reviewed for scientific and technical merit by an Initial
Review Group convened by the Division of Research Grants.  The other
review procedures remain unchanged.
 
For further information, contact:
 
Ronald N. Margolis, Ph.D.
Director, Endocrinology Research Program
Division of Diabetes, Endocrinology and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
Bethesda, MD  20892
Telephone:  (301) 496-7504
 
$$E2 END ************************************************************
 
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE
ADDRESS FOR THE WESTWOOD BUILDING IS:
 
5333 Westbard Avenue
Bethesda, MD  20816